World's First Patient-specific Pluripotent Stem Cell Company to Commercialize RGI`s Somatic Cell Reprogramming Technology; RGI and Tokyo Based JIG Establish ASCLEPIUS Therapeutics

Share Article

Asclepius Therapeutics to develop and commercialize RGI`s breakthrough "Stembrid" platform technology, the world's first success in somatic cell reprogramming.

Chicago based RGI and Japanese Cell Therapy company JIG establish Asclepius Therapeutics, to develop and commercialize the breakthrough "Stembrid" platform technology, the Worlds first success in Somatic cell reprogramming technology to create genetically matched pluripotent stem cells for therapeutic applications for a range of incurable illnesses from Parkinson's and heart disease to diabetes, Cancers, and spinal injuries.

JIG will begin clinical testing on Animals for safety and efficacy in 2007 in Taiwan and India, with JIG subsidiaries, RejuvaCell, Hygieia, and established research partnering hospitals.

After safety tests established JIG and Rejuvacell will begin testing on humans.

The "Stembrid" technique uses existing Embryonic stem cells instead of killing human eggs, no embryos or clones are created or destroyed, and solves all ethical problems. The Stembrid also offers great economical advantage over therapeutic cloning because of the high costs and dependence of human eggs, and enable the mass production of pluripotent stem cells that are genetically identical to the patients who suffer from incurable diseases and disorders. published online by Reproductive BioMedicine Online, rbmonline.com/Article/2071 November 2005. published in print -January 2006 issue

About JIG Corporation
JIG Corporation was established in 1999 by CEO James J. Ryan, Focused on finding a cure for his 3 year old bedridden son who suffers from a devastating illness. JIG has searched the world for top stem cell technologies and scientists. And now have world leading stem cell therapeutic technologies in:
1. Pluripotent stem cell therapeutic technology, (genetic matched)
2. Human Umbilical Cord Blood Stem cell therapy technology.
3. Bone marrow stem cell therapy technology (RejuvaCell).,
4. Blood derived Mononuclear cell technology
5. Scaffold Bio- Material.
JIG is focused on therapeutic application of stem cells to cure or treat intracable and incurable diseases, disorders,and illnesses.
JIG has long had a exclusive relationship to commercialize RGI technologies.

About RGI
RGI, the World`s leader in treating difficult infertility problems.World leader and pioneer in pre-implantation genetic diagnosis, and Under the leadership of CEO Dr. Yury Verlinsky, RGI is now the world`s leading and largest human morula and blastocyst derived Embryonic Stem cell bank with over 140 stem cell lines. RGI was the first in the World and largest bank with Diseased /Abnormal Stem cell lines for Research and Drug testing.
RGI`s cutting edge Stembrid technology can make Patient-specific stem cell Therapy possible without the need for cloning.

Contact:
James Ryan
elixcell (JIG), Inc
TEL:81-4-2929-3121

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

James Ryan
JIG/elixcell
81-50) 5806-5783
Email >
Visit website